CD8A and head and neck squamous cell carcinoma: In neoadjuvant therapy for resectable head and neck squamous cell carcinoma (HNSCC), the combination of relatlimab and nivolumab demonstrated safety and promising pathological responses compared to nivolumab monotherapy, highlighting emerging antitumor CD8+ T cell populations and targetable pathways in responder patients (Table 1) (56).